Advanced Cell Technologies
Region
Southern California
Fund
Anthem Venture Partners I
Industry
Other
About the Company
ACT is a biotechnology company applying human embryonic stem cell technology in the emerging field of regenerative medicine. New developments in stem cell biology, and ACT's research efforts in particular, have the potential to revolutionize medicine by enabling the production of human cells of any kind for use in a wide-array of therapies for immunological and age-related diseases. The company went public via a reverse merger in February, 2005.
Company Heritage
ACT was founded by Dr. Michael West, the founder of Geron Corporation (Nasdaq: GERN). ACT was one of the first companies to focus exclusively on human embryonic stem cell (hESC) therapies for the treatment of degenerative diseases. In 2001, ACT was first to announce that it had successfully completed human somatic cell nuclear transfer (therapeutic cloning). Since that time, ACT went public in 2005 (OCTBB: ACTC) and has focused on therapies for the treatment of macular degeneration with its retinal pigment epithelial (RPE) cell and cardiovascular disease with its myoblast technology. ACT is also focused on alternatives to generating hESC including single cell biopsy and cellular reprogramming.
Recent News •View All News
01/23/12
Some Promising Findings on Embryonic Stem Cells.
12/20/11
Marlboro company becomes focus of stem cell therapeutics
01/08/10
ACT Provides Update on IND Trial
11/19/09
ACT Files IND for Human Clinical Trial to Treat Eye Disease
05/28/09
US Company finds safer way to make stem-like cells
03/11/09
ACT Secures $5M credit facilty to pursue disease treatment to the eye.
